Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pentostatin
Drug ID BADD_D01730
Description A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Indications and Usage For the treatment of hairy cell leukaemia refractory to alpha interferon.
Marketing Status approved; investigational
ATC Code L01XX08
DrugBank ID DB00552
KEGG ID D00155
MeSH ID D015649
PubChem ID 439693
TTD Drug ID D0T3AD
NDC Product Code 42533-109; 67457-288; 0409-0801; 14096-124; 59981-005
UNII 395575MZO7
Synonyms Pentostatin | Deoxycoformycin | Imidazo(4,5-d)(1,3)diazepin-8-ol, 3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (R)- | 2'-Deoxycoformycin | 2' Deoxycoformycin | NSC-218321 | NSC 218321 | NSC218321 | Co-Vidarabine | CI-825 | CI 825 | CI825 | Nipent
Chemical Information
Molecular Formula C11H16N4O4
CAS Registry Number 53910-25-1
SMILES C1C(C(OC1N2C=NC3=C2NC=NCC3O)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oral candidiasis11.03.03.004; 07.05.07.001--Not Available
Osteoarthritis15.01.04.001--Not Available
Osteomyelitis15.02.05.001; 11.01.01.001--
Pain08.01.08.004--
Paraesthesia23.03.03.094; 17.02.06.005--
Paralysis17.01.04.004--Not Available
Pericardial effusion02.06.01.002--
Petechiae01.01.03.002; 24.07.06.004; 23.06.01.003--Not Available
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Phlebitis24.12.03.004; 12.02.01.002--
Photophobia06.01.01.004; 17.17.02.006--
Photosensitivity reaction23.03.09.003--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary oedema22.01.03.003; 02.05.02.0030.000336%
Pyrexia08.05.02.003--
Rash23.03.13.0010.000358%Not Available
Renal failure20.01.03.0050.000280%Not Available
Retinal disorder06.08.03.005--Not Available
Retinopathy24.03.07.003; 06.10.02.001--
Rhinitis11.01.13.004; 22.07.03.006--
Seizure17.12.03.0010.000168%
Sepsis11.01.11.003--
Shock24.06.02.002--Not Available
Sinus arrest02.03.03.007--Not Available
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages